Citizens Financial Group Inc. RI Buys 44,768 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Citizens Financial Group increased its Bristol Myers Squibb position by 58% during the third quarter, adding 44,768 shares and bringing its holdings to 121,997 shares valued at approximately $7.6 million.
• Institutional investors own 76.41% of Bristol Myers Squibb. Wall Street’s consensus rating is “Hold,” with an average price target of $64.88.
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share, exceeding estimates of $1.60, and revenue of $12.97 billion. The company also announced a quarterly dividend of $0.63 per share, representing an annualized yield of about 4.1%.

Citizens Financial Group Inc. RI raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 58.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 121,997 shares of the biopharmaceutical company's stock after acquiring an additional 44,768 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Bristol Myers Squibb were worth $7,613,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Altura Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 1.2% in the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company's stock worth $856,000 after purchasing an additional 161 shares during the period. Capital City Trust Co. FL grew its holdings in shares of Bristol Myers Squibb by 0.7% during the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company's stock valued at $1,455,000 after buying an additional 167 shares during the last quarter. Eagle Bay Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company's stock worth $408,000 after acquiring an additional 168 shares during the last quarter. Boltwood Capital Management boosted its stake in Bristol Myers Squibb by 2.5% during the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company's stock valued at $443,000 after purchasing an additional 170 shares during the last quarter. Finally, Sandy Cove Advisors LLC raised its stake in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after purchasing an additional 176 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Bank of America cut their price objective on shares of Bristol Myers Squibb from $71.00 to $66.00 in a report on Friday, October 9th. Roth Capital initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective for the company. UBS Group downgraded shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Citigroup reiterated a "neutral" rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Finally, Daiwa Securities Group boosted their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a "neutral" rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $64.88.

Bristol Myers Squibb Price Performance

BMY opened at $61.58 on Monday. The company has a market cap of $125.79 billion, a price-to-earnings ratio of 13.56, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The stock has a fifty day simple moving average of $63.26 and a two-hundred day simple moving average of $60.34.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the business posted $1.46 earnings per share. The business's revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is currently 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is currently owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.